Methylprednisolone-induced immune thrombocytopenia.

3. Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 2007;109(12):5477-5480. 4. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192. 5. Matsuda K, Nakazawa Y, Sakashita K, Shiohara M, Yamauchi K, Koike K. Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica. 2007;92(11):1576-1578. 6. Niemeyer CM, Kang M, Furlan I, et al. Germline mutations in CBL cause a predisposition to juvenile myelomonocytic leukemia [abstract]. Blood. 2009;114(22):Abstract 310. 7. Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of E3 ubiquitin ligase Cbl family members but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood. 2010;115(10):1969-1975.